Aileron Therapeutics Культура компании

Mr. Huw M. Nash, Ph.D. co-founded Aileron Therapeutics, Inc. in June 2005 and served as its Vice President of Corporate Development since June 2005. Mr. Nash was the Founding Scientist of NeoGenesis Pharmaceuticals. At NeoGenesis, Mr. Nash served as Vice President of External Collaborations, where he managed 21 research collaborations and also served as the principal technical representative for all business development, private financing and M&A activities. Dr. Nash received his B.A. in Biochemical Sciences from Harvard College and received his Ph.D. in organic chemistry from Harvard University.

Dr. Manuel C. Aivado, also known as Alves, M.D., Ph.D., has been the Chief Medical Officer, Chief Scientific Officer and Senior Vice President of Aileron Therapeutics, Inc. since September 2014. Dr. Aivado served as Vice President of Clinical Development & Pharmacovigilance at Taiho Oncology, Inc. from March 2012 to September 2014. Prior to Taiho, Dr. Aivado held positions of increasing responsibility at GlaxoSmithKline, Inc., including as Senior Medical Director in the Clinical Development group from October 2006 to March 2012, where he was involved in numerous drug programs including ofatumumab (Arzerra(R)), trametinib (Mekinist(R)), pazopanib (Votrient(R)), and eltrombopag (Promacta(R)). Prior to his industry experience, Dr. Aivado practiced clinical medicine in Germany for ten years. During his clinical career, he directed various molecular cancer research projects, which led him to be awarded the prestigious Dr. Mildred Scheel cancer research scholarship award in 2002. Dr. Aivado was previously an Instructor in Medicine at Beth Israel Deaconess Medical Center/Harvard Medical School, where he led the first ever-conducted proteomics research project in Myelodysplastic Syndromes (MDS). During his work in academia and in the pharmaceutical industry, Dr. Aivado's work has culminated in more than 50 peer-reviewed papers, including research articles in Lancet, Nature Genetics and PNAS. Dr. Aivado is a member of the American Society of Hematology and a member of the American Society of Clinical Oncology. He is a German Board-certified physician for Internal Medicine, Hematology and Medical Oncology. Dr. Aivado received an M.D. and Ph.D. from the Medical School of the University of Dusseldorf, in Germany.

Ms. Kira A. Nelson, CPA, has been Vice President of Finance and Operations at Aileron Therapeutics, Inc. since April 2015. From 1998 to March 2002, Ms. Nelson held various positions at Omtool, Ltd. Ms. Nelson served as Chief Financial Officer, Secretary and Treasurer of Omtool, Ltd. since April 2000 and also served as its Vice President of Finance since July 1998. Ms. Nelson served as Acting Chief Financial Officer, Secretary and Treasurer at Omtool' s from January 2000 to April 2000. She joined the Omtool in November 1996 and served as its Corporate Controller since July 1998. From 1997 to 1998, Ms. Nelson served as a Senior Financial Analyst at Discreet Logic, a developer of software for visual effects used in the creation of digital moving pictures. From February 2013 to April 2015, Ms. Nelson served as Director of Accounting and Finance at Aileron Therapeutics, Inc. From March 2002 to February 2013, Ms. Nelson was a Finance and Accounting Consultant to companies in various industries, including biotechnology, providing accounting and finance services. From 1991 to 1995, Ms. Ne lson served in various positions by Arthur Andersen LLP, where she served as a Senior Accountant in the Audit Division of its Boston office. Ms. Nelson began her career at Arthur Andersen LLP, where she became a Certified Public Accountant. Ms. Nelson received a B.A. from the College of the Holy Cross.

Mr. Donald V. Dougherty, CPA, CFA, also known as Don, has been Chief Financial Officer and Senior Vice President of Aileron Therapeutics, Inc. since June 8, 2017. Mr. Dougherty has more than 30 years of financial leadership experience. He is the Founder of Compound Capital Growth Investments (CCGrowth), LLC and has been its President since 1999. Prior to that, Mr. Dougherty held senior positions at several investment firms, including Essex Investment Management from 1994 to 1999, where he was a Principal, Portfolio Manager & Lead Biotechnology Analyst and at Putnam Investments from 1986 to 1994, where he was a Senior Vice President and Analyst in the Specialty Growth Group, which managed the Voyager, OTC Emerging Growth and Health Sciences funds. He began his investment career at Endowment Management Research in 1983. Mr. Dougherty received a B.A. from Williams College, an M.B.A. from New York University and his CPA and CFA early in his career.

Narayana Narasimhan serves as the Vice President of Aileron Therapeutics. Narayana started at Aileron Therapeutics in Aug of 2017. Narayana currently resides in the Greater Boston Area.

Don Dougherty serves as the Chief Financial Officer of Aileron Therapeutics. Don started at Aileron Therapeutics in Jun of 2017. Don currently resides in the Greater Boston Area.

Allen Annis serves as the Vice President Research of Aileron Therapeutics. Allen currently resides in the Greater Boston Area.

Kathleen Large serves as the Vice President Development Operations of Aileron Therapeutics. Kathleen currently resides in the Greater Boston Area.